But this is not the same as stopping a DMT in a patient who is clinically quiescent for several or many years. Both papers describe the small number of case reports and natural history studies which clearly demonstrate treatment interruption in young MS patients with substantial pretreatment relapse and/or MRI activity is a very bad idea. They also correctly point out that clinical equipoise remains, however, for the more challenging question of deliberate DMT discontinuation due to perceived lack of need in aging, clinically and radiographically inactive (no new relapses or brain MRI lesions) MS patients.
This dearth of information has been addressed in a small number of recent papers, 6-10 all of which suffer methodological limitations, some more significant than others. The mean age of discontinuation is between 38 and 50 years in all but one 8 study, so the patients are relatively young. Only two 6,8 report results exclusively with patients who deliberately stopped DMT due to clinical inactivity (one 9 included some who did). In the others, patients stopped for many different reasons (intolerance, pregnancy, insurance interruption, etc.). Only two 6, 8 are prospective. MRI data are missing from many of the patients, or not obtained. 10 One is propensity-matched, 10 one 6 has a poorly matched comparator group, and three have no control group. None are blinded as to outcome measures, nor do any have true pretreatment data that would ascertain those with more or less active disease prior to starting a DMT. All, however, have come to the same general conclusion that older patients with absent clinical and MRI activity for extended periods of time while taking a DMT have modest, but some, risk of recurrence or worsening after DMT discontinuation. Concerns have been raised in both arguments, 1,2 and in one 6 of the recent papers addressing this issue, that discontinuation of more highly effective medications, especially natalizumab, may be associated with enhanced risk of recurrence. This worry, however, does not adequately take into account the severity of disease activity prior to starting more highly effective therapy. Until more highly effective therapies are used consistently as first-line agents, not primarily as escalation therapy in those failing less effective DMTs, it is unlikely that analyses of this nature will provide useful information to answer this important question.
Going forward, several things will be needed to more completely answer this question and give patients and practitioners the greatest confidence that a DMT discontinuation trial is reasonable. In their 2015 paper 11 on this topic, Tobin and Weinshenker outlined their vision of a randomized, controlled, discontinuation trial, and as of spring 2017, we are recruiting for a study very similar to what they described (DISCOMS [NCT03073603]). Patients 55 years and older with no relapses or new brain MRI lesions for 5 or more years will be randomized to continue their DMT or not, and be prospectively followed for 2 years, with the primary outcome being percentage of patients who relapse or have new brain MRI lesions. Secondary measures include percentage with disability progression and a variety of patient-reported outcomes. The latter are particularly important, as there is also no good understanding of patient attitudes as to how much recurrent disease activity may be acceptable in exchange for the potential benefits of DMT discontinuation (which might include reduced side effects, risks, costs, and reminders of having MS, among others). Subgroup analysis will, hopefully, identify those at low and high risk of recurrence. Other studies based on these results will likely follow. Second, more advanced MRI or other radiological techniques (e.g. positron emission tomography) may be able to identify markers of ongoing inflammatory disease activity that would portend reactivation of clinical disease upon removal of DMT, as may a blood biomarker. Finally, the apparent reduction in efficacy of the presently available DMTs in the aging MS patient, at a time when many are experiencing progressive disability, should be a reminder that there remains a critical need to develop therapies directed toward this patient population. These might be focused on the meningeal infiltrates, cortical abnormalities, and microglial activation seen more prominently in progressive MS, but also should include neuroprotective and regenerative approaches focused on repair.
